Research opens new doors to treating glaucoma
By Jan Jarvis
Glucocorticoids are often used to reduce inflammation, reduce pain and treat many conditions such as allergies and rashes. But for some people, the very drugs that treats one condition can cause another: specifically, glaucoma.
The condition, which affects more than 64.3 million people, is the second-leading cause of irreversible blindness in the world. Still, little is known about why glucocorticoid therapy elevates intraocular pressure and raises the risk of developing this disease, said Gulab Zode, PhD, Assistant Professor in Pharmacology & Neuroscience.
“We know that when people are treated with glucocorticoids, one of the possible side effects is increased intraocular pressure,” he said. “About 30 percent to 40 percent of patients develop this and if they don’t get treated, they experience vision loss.”
In a paper recently published in the Journal of Biological Chemistry, a team of scientists led by Dr. Zode discovered how glucocorticoids elevate intraocular pressure in the eye.
“There are no treatments that target the pathology of this disease, there are only drugs that act on the symptoms,” he said, “I want to know what causes the damage so that a targeted treatment could be developed.”
For years, Dr. Zode’s research has focused on what causes damage to the trabecular meshwork, a specialized tissue in the eye that maintains normal intraocular pressure by regulating aqueous humor outflow resistance.
In this article, Dr. Zode’s lab identified that glucocorticoids increase the transforming growth factor B2, which further contributes to elevation of intraocular pressure. The study establishes a central role for transforming growth factor B2 in glucocorticoid-induced glaucoma and provides therapeutic targets for the reduction of increased intraocular pressure in the eye.
“Now that we can see how transforming growth factor B2 plays a role in intraocular pressure elevation, we can block this signaling pathway,” he said. “This opens the door to the possibility of targeted treatment.”
By Jan Jarvis The first study of a blood test to detect Alzheimer’s disease within a primary care setting soon will be conducted at UNT Health Science Center. The simple test could be a game-changer in the diagnosis of early Alzheimer’s. If successful, it would be possible to ide...Read more
Jul 12, 2018
By Jeff Carlton Charles Taylor, PharmD, who has presided over a number of critical academic milestones as Dean of the UNT System College of Pharmacy, will become Provost and Executive Vice President of Academic Affairs at UNT Health Science Center. Dr. Taylor said he was “excited, honore...Read more
Jul 11, 2018
The UNT Health Science Center, all clinics staffed by UNT Health physicians, and the Fitness Center will be closed on Wednesday, July 4, 2018, for the Independence Day holiday. The Lewis Library will be open, with abbreviated hours on July 3 and 4. Have a safe and healthy Independence Day!...Read more
Jul 3, 2018
By Alex Branch John Mills, DO, has led by example all his life. As a U.S. Army helicopter pilot during the Vietnam War, he flew reconnaissance missions behind enemy lines, accumulating 832 combat hours. As a physician, he practiced medicine in West Texas because he saw the scarce medic...Read more
Jul 2, 2018